Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Astria Therapeutics, Inc. (ATXS)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
9.04+0.13 (+1.46%)
At close: 04:00PM EDT
9.04 0.00 (0.00%)
After hours: 05:36PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close8.91
Open8.99
Bid8.47 x 900
Ask9.12 x 1100
Day's Range8.78 - 9.38
52 Week Range2.36 - 10.70
Volume78,961
Avg. Volume193,107
Market Cap137.209M
Beta (5Y Monthly)1.19
PE Ratio (TTM)N/A
EPS (TTM)-5.74
Earnings DateNov 08, 2022 - Nov 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est21.80
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ATXS

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Astria Therapeutics, Inc.
    Daily – Vickers Top Buyers & Sellers for 09/16/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    17 days agoArgus Research
View more
  • Business Wire

    Astria Therapeutics to Host Virtual R&D Day: Update on STAR-0215 and Its Clinical Development

    BOSTON, September 16, 2022--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that the Company will host a virtual R&D Day titled "Update on STAR-0215 and Its Clinical Development for the Prevention of HAE Attacks" on September 30th from 10:30am to 12:00pm ET. The event will feature a presentation by Dr. Marc Riedl,

  • Business Wire

    Astria Therapeutics to Present at Upcoming Investment Conferences

    BOSTON, September 06, 2022--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that the Company will be presenting at two upcoming investment conferences:

  • Business Wire

    Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BOSTON, September 02, 2022--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, granted stock options to purchase 5,500 shares of Astria’s common stock on September 1, 2022 under Astria’s 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to ind

Advertisement
Advertisement